BCRX Posts Q3 Operating Profit of $53.3M as ORLADEYO Pellets Expand to Ages 12+
Market Chameleon (Wed, 4-Nov 8:35 AM)
BioCryst Wins FDA Approval for ORLADEYO 150 mg Oral Pellets, Extending a Once-Daily Option for HAE Patients 12+
Market Chameleon (Wed, 21-Oct 8:14 AM)